Business Context and Reporting Period
Company: Charles River Laboratories International, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2025
Subject: Conclusion of SEC investigation and independent internal review regarding the sourcing of non-human primates and related disclosures.
Key Financial Metrics
This filing is a current report regarding legal and regulatory events. It does not contain financial statements, revenue figures, profit data, cash flow information, margins, debt levels, or liquidity metrics.
Material Changes
The primary material change reported is the resolution of a regulatory matter initiated on May 16, 2023. The SEC's Division of Enforcement has concluded its investigation and does not intend to recommend an enforcement action against the Company. Additionally, the Company's independent investigation, conducted by counsel retained by the Audit Committee, has concluded with no material findings.
Guidance, Outlook, and Risks
Management Commentary: The Company confirms that both the external SEC inquiry and the internal independent investigation have been closed without adverse findings or recommended enforcement actions.
Risks and Contingencies: The filing addresses the resolution of a specific risk related to regulatory scrutiny over non-human primate sourcing. No new risks or contingencies are introduced in this document.
Investor Verification Checklist
- Verify the date of the SEC notification confirming the conclusion of the investigation (November 14, 2025).
- Confirm the scope of the original inquiry (sourcing of non-human primates and related disclosures).
- Note that the independent investigation yielded no material findings.
- Understand that this filing contains no financial performance data or forward-looking guidance.